QTTB insider transaction filings
Q32 Bio Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-27. Screen QTTB transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 15 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 3 filings by 3 insiders — 16,615 shares, $275,144 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
- Largest priced transaction: sale of 9,845 shares @ $16.56 ($163,033) by Morrison Jodie Pope, filed 2026-08-27.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Morrison Jodie Pope — CEO, Director | 2 | — | 1 leg · 9,845 sh · $163,033 | 1 |
| Kalowski Lee — CFO and President | 2 | — | 1 leg · 3,972 sh · $65,776 | 1 |
| Violette Shelia M. — Chief Scientific Officer | 2 | — | 1 leg · 2,798 sh · $46,335 | 1 |
| Manke Isaac — Director | 2 | — | — | 3 |
| GRAYZEL DAVID S. — Director | 1 | — | — | 1 |
| Iwicki Mark T — Director | 1 | — | — | 1 |
| LAPORTE KATHLEEN — Director | 1 | — | — | 1 |
| Lundberg Sven Ante — Director | 1 | — | — | 1 |
| TZIANABOS ARTHUR — Director | 1 | — | — | 1 |
| Thistle Mary — Director | 1 | — | — | 1 |
+1 more insider in the window, not shown — every filing appears in the table below.
Recent Form 4 filings — Q32 Bio Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-27 | 4 | Violette Shelia M. — Chief Scientific Officer | Sale (S): 2,798 @ $16.56 | EDGAR |
| 2026-08-27 | 4 | Kalowski Lee — CFO and President | Sale (S): 3,972 @ $16.56 | EDGAR |
| 2026-08-27 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 9,845 @ $16.56 | EDGAR |
| 2026-07-21 | 4/A | Lundberg Sven Ante — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Xu Diyong — Director, 10% owner | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | GRAYZEL DAVID S. — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Manke Isaac — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | TZIANABOS ARTHUR — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Iwicki Mark T — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | Thistle Mary — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4/A | LAPORTE KATHLEEN — Director | Grant/award (A): 10,826 (derivative) @ $0 | EDGAR |
| 2026-07-20 | 4 | Violette Shelia M. — Chief Scientific Officer | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-07-20 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 | EDGAR |
| 2026-07-20 | 4 | Morrison Jodie Pope — CEO, Director | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-07-02 | 4 | Manke Isaac — Director | Option exercise (M): 53,521 @ $2.80 · Option exercise (M): 53,521 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Xu Diyong — Director, 10% owner | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Manke Isaac — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | TZIANABOS ARTHUR — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Iwicki Mark T — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Thistle Mary — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 9,810 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Xu Diyong — Director, 10% owner | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-06-01 | 4 | ORBIMED ADVISORS LLC — Director, 10% owner OrbiMed Capital GP VII LLC — Director, 10% owner OrbiMed Genesis GP LLC — Director, 10% owner | Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8 | EDGAR |
| 2026-03-20 | 4 | Violette Shelia M. — Chief Scientific Officer | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2026-03-20 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 | EDGAR |
| 2026-03-20 | 4 | Morrison Jodie Pope — CEO, Director | Grant/award (A): 132,000 @ $0 | EDGAR |
| 2026-02-27 | 4 | Violette Shelia M. — Chief Scientific Officer | Sale (S): 2,815 @ $4.51 | EDGAR |
| 2026-02-27 | 4 | Kalowski Lee — CFO and President | Sale (S): 3,995 @ $4.51 | EDGAR |
| 2026-02-27 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 9,896 @ $4.51 | EDGAR |
| 2026-01-30 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 16,363 (derivative) @ $2.75 | EDGAR |
| 2026-01-30 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 20,363 (derivative) @ $2.75 | EDGAR |
| 2026-01-30 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 23,272 (derivative) @ $2.75 | EDGAR |
| 2025-12-04 | 4 | Kalowski Lee — CFO and President | Sale (S): 9,072 @ $3.46 | EDGAR |
| 2025-12-04 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 22,506 @ $3.46 | EDGAR |
| 2025-10-27 | 4 | Lundberg Sven Ante — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Xu Diyong — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Manke Isaac — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | TZIANABOS ARTHUR — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Iwicki Mark T — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | Thistle Mary — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-10-27 | 4 | LAPORTE KATHLEEN — Director | Grant/award (A): 53,521 (derivative) @ $0 | EDGAR |
| 2025-08-28 | 4 | Violette Shelia M. — Chief Scientific Officer | Sale (S): 2,990 @ $1.80 | EDGAR |
| 2025-08-28 | 4 | Kalowski Lee — CFO and President | Sale (S): 4,240 @ $1.80 | EDGAR |
| 2025-08-28 | 4 | Morrison Jodie Pope — CEO, Director | Sale (S): 10,494 @ $1.80 | EDGAR |
| 2025-02-27 | 4 | Kalowski Lee — CFO and President | Grant/award (A): 53,250 @ $0 · Disposition to issuer (D): 16,901 (derivative) @ $0 · Grant/award (A): 16,901 (derivative) @ $0 · Disposition to issuer (D): 161,323 (derivative) @ $0 · Grant/award (A): 161,323 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | TZIANABOS ARTHUR — Director | Disposition to issuer (D): 25,674 (derivative) @ $0 · Grant/award (A): 25,674 (derivative) @ $0 · Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
| 2025-02-27 | 4 | LAPORTE KATHLEEN — Director | Disposition to issuer (D): 5,431 (derivative) @ $0 · Grant/award (A): 5,431 (derivative) @ $0 · Disposition to issuer (D): 1,947 (derivative) @ $0 · Grant/award (A): 1,947 (derivative) @ $0 · Disposition to issuer (D): 12,767 (derivative) @ $0 · Grant/award (A): 12,767 (derivative) @ $0 | EDGAR |
Recent 8-K events — Q32 Bio Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-13 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=QTTB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →